Drug Class
anthracyclines and related substances

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for cyclophosphamide
  2. FDA Label for daunorubicin
  3. FDA Label for doxorubicin
  4. FDA Label for epirubicin
  5. FDA Label for idarubicin
  6. FDA Label for mitoxantrone







PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for anthracyclines and related substances

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1001179 NC_000011.10:g.34438684C>T, NC_000011.9:g.34460231C>T, NG_013339.1:g.4760C>T, NM_001752.3:c.-330C>T, rs17879971, rs36224099, rs386508782, rs60285691
C > T
SNP
No VIP available CA VA
rs10426377 NC_000019.10:g.48588977C>A, NC_000019.9:g.49092234C>A, NG_029063.1:g.41806C>A, NM_004605.2:c.378+1540C>A, NM_177973.1:c.423+1540C>A, XM_005259182.1:c.-228C>A, XM_005259182.2:c.-228C>A, rs61651031
C > A
SNP
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available CA VA
rs1056892 NC_000021.8:g.37518706G>A, NC_000021.9:g.36146408G>A, NM_001236.3:c.730G>A, NP_001227.1:p.Val244Met, NR_038892.1:n.93-53C>T, NR_038893.1:n.93-53C>T, NR_038894.1:n.93-53C>T, rs3171445, rs52816011, rs58776388
G > A
SNP
V244M
No VIP available CA VA
rs10836235 NC_000011.10:g.34439157C>T, NC_000011.9:g.34460704C>T, NG_013339.1:g.5233C>T, NM_001752.3:c.66+78C>T, rs17886119
C > G
C > T
SNP
No VIP available CA VA
rs11155012 NC_000006.11:g.139151784G>A, NC_000006.12:g.138830647G>A, NM_001077706.2:c.180-7705G>A, NM_001195037.2:c.180-7705G>A, XM_006715472.2:c.180-7705G>A, XM_011535795.1:c.180-7705G>A, XM_011535796.1:c.231-7705G>A, XM_011535797.1:c.-28-7705G>A, XR_943064.1:n.208C>T, XR_943065.1:n.213C>T, rs56479252, rs58466605
G > A
SNP
No VIP available CA VA
rs1149222 NC_000007.13:g.87073775G>T, NC_000007.14:g.87444459G>T, NG_007118.1:g.40974C>A, NM_000443.3:c.1119+403C>A, NM_018849.2:c.1119+403C>A, NM_018850.2:c.1119+403C>A, XM_011516308.1:c.1119+403C>A, XM_011516309.1:c.1119+403C>A, XM_011516310.1:c.1119+403C>A, XM_011516311.1:c.1119+403C>A, XM_011516312.1:c.1119+403C>A, XM_011516313.1:c.1119+403C>A, XM_011516314.1:c.1140+403C>A, XM_011516315.1:c.459+403C>A, XR_927478.1:n.1215+403C>A, rs10376488, rs1639242, rs17297653, rs60948017
G > T
SNP
No VIP available No Clinical Annotations available VA
rs1374749 NC_000002.11:g.46596433G>A, NC_000002.12:g.46369294G>A, NG_016000.1:g.76893G>A, NM_001430.4:c.780-533G>A, XM_011532698.1:c.819-533G>A, rs58613482
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1629140 NC_000014.8:g.34413826A>G, NC_000014.9:g.33944620A>G, NM_001308103.1:c.75+6058T>C, NM_022073.3:c.357+5776T>C, XM_006720015.2:c.75+6058T>C, rs17506218, rs60386310
A > G
SNP
No VIP available CA VA
rs1736557 NC_000001.10:g.171080080G>A, NC_000001.11:g.171110939G>A, NG_012690.1:g.25063G>A, NM_001002294.2:c.769G>A, NM_001319173.1:c.709G>A, NM_001319174.1:c.580G>A, NM_006894.4:c.769G>A, NM_006894.5:c.769G>A, NP_001002294.1:p.Val257Met, NP_001306102.1:p.Val237Met, NP_001306103.1:p.Val194Met, NP_008825.4:p.Val257Met, XM_005245043.1:c.709G>A, XM_005245044.1:c.580G>A, XM_011509345.1:c.709G>A, XM_011509346.1:c.709G>A, XP_005245100.1:p.Val237Met, XP_005245101.1:p.Val194Met, XP_011507647.1:p.Val237Met, XP_011507648.1:p.Val237Met, rs17845981, rs17858963, rs56477964, rs58508781
G > A
SNP
V257M
No VIP available CA VA
rs17583889 NC_000002.11:g.138746039C>A, NC_000002.12:g.137988469C>A, NG_012966.1:g.29232C>A, NM_006895.2:c.191-12449C>A, XM_005263654.1:c.191-12449C>A, XM_011511063.1:c.89-12449C>A, XM_011511064.1:c.-188-12449C>A
C > A
SNP
No VIP available CA VA
rs17645700 NC_000002.11:g.138780932T>C, NC_000002.12:g.138023362T>C, XR_244863.1:n.579-15566A>G
T > C
SNP
No VIP available CA VA
rs17863783 NC_000002.11:g.234602277G>T, NC_000002.12:g.233693631G>T, NG_002601.2:g.108888G>T, NM_001072.3:c.627G>T, NM_019075.2:c.855+56254G>T, NM_019076.4:c.856-73403G>T, NM_019077.2:c.855+10839G>T, NM_021027.2:c.855+20842G>T, NM_205862.1:c.-7-168G>T, NP_001063.2:p.Val209=, XR_241240.1:n.788G>T, XR_241241.1:n.941+20842G>T, rs60686635
G > T
SNP
V209V
No VIP available CA No Variant Annotations available
rs1799983 NC_000007.13:g.150696111T>G, NC_000007.14:g.150999023T>G, NG_011992.1:g.12965T>G, NM_000603.4:c.894T>G, NM_001160109.1:c.894T>G, NM_001160110.1:c.894T>G, NM_001160111.1:c.894T>G, NP_000594.2:p.Asp298Glu, NP_001153581.1:p.Asp298Glu, NP_001153582.1:p.Asp298Glu, NP_001153583.1:p.Asp298Glu, XM_006716002.2:c.894T>G, XP_006716065.1:p.Asp298Glu, rs11266811, rs13238975, rs13305983, rs13308813, rs17173672, rs3730304, rs57135373
T > G
SNP
D298E
No VIP available CA VA
rs1800566 NC_000016.10:g.69711242G>A, NC_000016.9:g.69745145G>A, NG_011504.1:g.20389C>T, NM_000903.2:c.559C>T, NM_001025433.1:c.457C>T, NM_001025434.1:c.445C>T, NM_001286137.1:c.343C>T, NP_000894.1:p.Pro187Ser, NP_001020604.1:p.Pro153Ser, NP_001020605.1:p.Pro149Ser, NP_001273066.1:p.Pro115Ser, XM_005255830.1:c.343C>T, XP_005255887.1:p.Pro115Ser, rs4134727, rs4149351, rs57135274
G > A
SNP
P187S
No VIP available CA VA
rs2019604 NC_000016.10:g.89549357T>G, NC_000016.9:g.89615765T>G, NG_008082.1:g.45961T>G, NM_003119.3:c.1664-1137T>G, XM_005256320.1:c.-21+2427T>G, XM_006721264.2:c.1664-1137T>G, rs17783931, rs3888234, rs57996679, rs74251519
T > G
SNP
No VIP available No Clinical Annotations available VA
rs2020870 NC_000001.10:g.171154959A>G, NC_000001.11:g.171185820A>G, NM_001301347.1:c.-386+461A>G, NM_001460.4:c.107A>G, NP_001451.2:p.Asp36Gly, XM_005245039.1:c.107A>G, XP_005245096.1:p.Asp36Gly, XR_426768.2:n.224A>G, XR_921761.1:n.224A>G, XR_922278.1:n.508-17632T>C, rs2266712, rs52821140, rs58458262
A > G
SNP
D36G
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available CA VA
rs2108623 NC_000019.10:g.15906196G>A, NC_000019.9:g.16017006G>A, rs17454858, rs3947944, rs4429395, rs59294251
G > A
SNP
No VIP available CA VA
rs2229774 NC_000012.11:g.53605545G>A, NC_000012.12:g.53211761G>A, NG_029822.1:g.25496C>T, NM_000966.5:c.1280C>T, NM_001042728.2:c.1247C>T, NM_001243730.1:c.1064C>T, NM_001243731.1:c.917C>T, NM_001243732.1:c.1214C>T, NP_000957.1:p.Ser427Leu, NP_001036193.1:p.Ser416Leu, NP_001230659.1:p.Ser355Leu, NP_001230660.1:p.Ser306Leu, NP_001230661.1:p.Ser405Leu, XM_005269054.1:c.1541C>T, XM_005269054.2:c.1541C>T, XM_005269055.1:c.1541C>T, XM_005269055.2:c.1541C>T, XM_005269056.1:c.1280C>T, XM_005269056.2:c.1280C>T, XM_005269057.1:c.1280C>T, XM_011538628.1:c.1064C>T, XP_005269111.1:p.Ser514Leu, XP_005269112.1:p.Ser514Leu, XP_005269113.1:p.Ser427Leu, XP_005269114.1:p.Ser427Leu, XP_011536930.1:p.Ser355Leu, rs116930311, rs61642612
G > A
SNP
S427L
No VIP available CA VA
rs2232228 NC_000016.10:g.69109674A>G, NC_000016.9:g.69143577A>G, NM_001199280.1:c.279A>G, NM_005329.2:c.279A>G, NM_138612.2:c.279A>G, NP_001186209.1:p.Ala93=, NP_005320.2:p.Ala93=, NP_619515.1:p.Ala93=, XM_005255919.1:c.687A>G, XM_005255920.1:c.279A>G, XM_005255921.1:c.279A>G, XM_011523061.1:c.279A>G, XP_005255976.1:p.Ala229=, XP_005255977.1:p.Ala93=, XP_005255978.1:p.Ala93=, XP_011521363.1:p.Ala93=, rs17845662, rs17858598, rs3743679, rs61175697
A > G
SNP
A93A
No VIP available CA VA
rs2235047 NC_000007.13:g.87138532A>C, NC_000007.14:g.87509216A>C, NG_011513.1:g.209033T>G, NM_000927.4:c.3489+59T>G, rs386562025, rs56488245, rs57169649, rs58701659
A > C
SNP
No VIP available CA VA
rs2290271 NC_000015.10:g.84904404A>C, NC_000015.9:g.85447635A>C, NM_001287761.1:c.603+166A>C, NM_001287762.1:c.603+166A>C, NM_004213.4:c.603+166A>C, XM_005254988.1:c.603+166A>C, XM_005254989.1:c.603+166A>C, XM_005254990.1:c.603+166A>C, XM_005254991.1:c.603+166A>C, XM_005254992.1:c.576+166A>C, XM_005254993.1:c.603+166A>C, XM_005254994.1:c.369+166A>C, XM_005254995.1:c.603+166A>C, XM_011522203.1:c.603+166A>C, XM_011522204.1:c.603+166A>C, XM_011522205.1:c.603+166A>C, XM_011522206.1:c.603+166A>C, XM_011522207.1:c.603+166A>C, XM_011522208.1:c.576+166A>C, XM_011522209.1:c.603+166A>C, XM_011522210.1:c.603+166A>C, XM_011522211.1:c.369+166A>C, XM_011522212.1:c.603+166A>C, XM_011522213.1:c.603+166A>C, XM_011522214.1:c.603+166A>C, XM_011522215.1:c.603+166A>C, XM_011522216.1:c.369+166A>C, XM_011522217.1:c.603+166A>C, XM_011522218.1:c.603+166A>C, XR_931944.1:n.809+166A>C, XR_931945.1:n.809+166A>C, rs17608700, rs56963765
A > C
SNP
No VIP available CA VA
rs2305364 NC_000015.10:g.84909044T>C, NC_000015.9:g.85452275T>C, NM_001287761.1:c.795+249T>C, NM_001287762.1:c.795+249T>C, NM_004213.4:c.795+249T>C, XM_005254988.1:c.795+249T>C, XM_005254989.1:c.795+249T>C, XM_005254990.1:c.795+249T>C, XM_005254991.1:c.795+249T>C, XM_005254992.1:c.768+249T>C, XM_005254993.1:c.717+3392T>C, XM_005254994.1:c.561+249T>C, XM_005254995.1:c.795+249T>C, XM_011522203.1:c.795+249T>C, XM_011522204.1:c.795+249T>C, XM_011522205.1:c.795+249T>C, XM_011522206.1:c.795+249T>C, XM_011522207.1:c.795+249T>C, XM_011522208.1:c.768+249T>C, XM_011522209.1:c.717+3392T>C, XM_011522210.1:c.795+249T>C, XM_011522211.1:c.561+249T>C, XM_011522212.1:c.795+249T>C, XM_011522213.1:c.795+249T>C, XM_011522214.1:c.795+249T>C, XM_011522215.1:c.795+249T>C, XM_011522216.1:c.561+249T>C, XM_011522217.1:c.795+249T>C, XM_011522218.1:c.795+249T>C, XR_931944.1:n.1001+249T>C, XR_931945.1:n.1001+249T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3025030 NC_000006.11:g.43750587G>C, NC_000006.12:g.43782850G>C, NG_008732.1:g.17635G>C, NM_001025366.2:c.1217+763G>C, NM_001025367.2:c.1148+763G>C, NM_001025368.2:c.1094+763G>C, NM_001025369.2:c.1059+798G>C, NM_001025370.2:c.963-1691G>C, NM_001033756.2:c.1094+763G>C, NM_001171622.1:c.933-1691G>C, NM_001171623.1:c.677+763G>C, NM_001171624.1:c.626+763G>C, NM_001171625.1:c.608+763G>C, NM_001171626.1:c.554+763G>C, NM_001171627.1:c.519+798G>C, NM_001171628.1:c.423-1691G>C, NM_001171629.1:c.554+763G>C, NM_001171630.1:c.393-1691G>C, NM_001204384.1:c.495-1691G>C, NM_001204385.1:c.1035-1691G>C, NM_001287044.1:c.470+763G>C, NM_001317010.1:c.554+763G>C, NM_003376.5:c.1166+763G>C, XM_005249363.1:c.470+763G>C, rs16896816, rs3799959, rs61356923
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3025033 NC_000006.11:g.43751075A>G, NC_000006.12:g.43783338A>G, NG_008732.1:g.18123A>G, NM_001025366.2:c.1218-1203A>G, NM_001025367.2:c.1149-1203A>G, NM_001025368.2:c.1095-1203A>G, NM_001025369.2:c.1060-1203A>G, NM_001025370.2:c.963-1203A>G, NM_001033756.2:c.1094+1251A>G, NM_001171622.1:c.933-1203A>G, NM_001171623.1:c.678-1203A>G, NM_001171624.1:c.627-1203A>G, NM_001171625.1:c.609-1203A>G, NM_001171626.1:c.555-1203A>G, NM_001171627.1:c.520-1203A>G, NM_001171628.1:c.423-1203A>G, NM_001171629.1:c.554+1251A>G, NM_001171630.1:c.393-1203A>G, NM_001204384.1:c.495-1203A>G, NM_001204385.1:c.1035-1203A>G, NM_001287044.1:c.471-1203A>G, NM_001317010.1:c.555-1203A>G, NM_003376.5:c.1167-1203A>G, XM_005249363.1:c.471-1203A>G, rs3778502, rs59547322
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3025039 NC_000006.11:g.43752536C>T, NC_000006.12:g.43784799C>T, NG_008732.1:g.19584C>T, NM_001025366.2:c.*237C>T, NM_001025367.2:c.*237C>T, NM_001025368.2:c.*237C>T, NM_001025369.2:c.*253C>T, NM_001025370.2:c.*237C>T, NM_001033756.2:c.*171C>T, NM_001171622.1:c.*237C>T, NM_001171623.1:c.*237C>T, NM_001171624.1:c.*237C>T, NM_001171625.1:c.*237C>T, NM_001171626.1:c.*237C>T, NM_001171627.1:c.*253C>T, NM_001171628.1:c.*237C>T, NM_001171629.1:c.*171C>T, NM_001171630.1:c.*237C>T, NM_001204384.1:c.*237C>T, NM_001204385.1:c.*237C>T, NM_001287044.1:c.*237C>T, NM_001317010.1:c.*171C>T, NM_003376.5:c.*237C>T, XM_005249363.1:c.*237C>T, rs11575898
C > T
SNP
No VIP available CA VA
rs316019 NC_000006.11:g.160670282A>C, NC_000006.12:g.160249250A>C, NM_003058.3:c.808T>G, NP_003049.2:p.Ser270Ala, rs1755917, rs17846267, rs17859289, rs386580336, rs52803175, rs60007366, rs666224
A > C
SNP
S270A
No VIP available No Clinical Annotations available VA
rs3768728 NC_000002.11:g.46590791T>C, NC_000002.12:g.46363652T>C, NG_016000.1:g.71251T>C, NM_001430.4:c.779+2562T>C, XM_011532698.1:c.818+2562T>C, rs60273833
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3892097 NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227
C > T
SNP
No VIP available CA VA
rs4148350 NC_000016.10:g.16076620G>T, NC_000016.9:g.16170477G>T, NG_028268.1:g.132044G>T, NM_004996.3:c.1988+219G>T, NT_187607.1:g.1734472G>T, XM_005255326.1:c.1988+219G>T, XM_005255327.1:c.1862+219G>T, XM_005255328.1:c.1850+219G>T, XM_005255329.1:c.1988+219G>T, XM_011522497.1:c.1964+219G>T, XM_011522498.1:c.1895+219G>T, rs587779726, rs60127316
G > T
SNP
No VIP available CA VA
rs4148808 NC_000007.13:g.87105795T>C, NC_000007.14:g.87476479T>C, NG_007118.1:g.8954A>G, NM_000443.3:c.-852A>G, NM_018849.2:c.-852A>G, NM_018850.2:c.-852A>G, XM_011516308.1:c.-715A>G, XM_011516309.1:c.-715A>G, XM_011516310.1:c.-715A>G, XM_011516311.1:c.-715A>G, XM_011516312.1:c.-715A>G, XM_011516313.1:c.-715A>G, XM_011516314.1:c.-332A>G, XR_927478.1:n.-619A>G, rs386591494, rs59666582
T > C
SNP
No VIP available CA VA
rs4261716 NC_000002.11:g.234593117G>T, NC_000002.12:g.233684471G>T, NG_002601.2:g.99728G>T, NM_019075.2:c.855+47094G>T, NM_019076.4:c.855+65909G>T, NM_019077.2:c.855+1679G>T, NM_021027.2:c.855+11682G>T, XM_005246081.1:c.855+1679G>T, XR_241241.1:n.941+11682G>T, rs17683792, rs58252906
G > T
SNP
No VIP available CA VA
rs4877847 NC_000009.11:g.86946417A>C, NC_000009.12:g.84331502A>C, NM_001199633.1:c.60+9072T>G, NM_022127.2:c.60+9072T>G, NR_037638.2:n.206+9072T>G, XM_011518905.1:c.60+9072T>G, XM_011518906.1:c.60+9072T>G, XM_011518907.1:c.-97-18048T>G, XM_011518909.1:c.60+9072T>G, XM_011518910.1:c.60+9072T>G, XR_929832.1:n.187+9072T>G
A > C
SNP
No VIP available No Clinical Annotations available VA
rs4880 NC_000006.11:g.160113872A>G, NC_000006.12:g.159692840A>G, NG_008729.1:g.5482T>C, NM_000636.2:c.47T>C, NM_001024465.1:c.47T>C, NM_001024466.1:c.47T>C, NP_000627.2:p.Val16Ala, NP_001019636.1:p.Val16Ala, NP_001019637.1:p.Val16Ala, rs1141717, rs11551083, rs116851270, rs17362379, rs17405198, rs17856520, rs1799725, rs3205539, rs386596107
A > G
SNP
V16A
No VIP available No Clinical Annotations available VA
rs4953344 NC_000002.11:g.46552458T>C, NC_000002.12:g.46325319T>C, NG_016000.1:g.32918T>C, NM_001430.4:c.27-21554T>C, XM_011532698.1:c.-493T>C, XR_940055.1:n.2355+10465A>G, rs17746007, rs56802594
T > C
SNP
No VIP available CA VA
rs6759892 NC_000002.11:g.234601669T>G, NC_000002.12:g.233693023T>G, NG_002601.2:g.108280T>G, NM_001072.3:c.19T>G, NM_019075.2:c.855+55646T>G, NM_019076.4:c.856-74011T>G, NM_019077.2:c.855+10231T>G, NM_021027.2:c.855+20234T>G, NM_205862.1:c.-7-776T>G, NP_001063.2:p.Ser7Ala, XR_241240.1:n.180T>G, XR_241241.1:n.941+20234T>G, rs17670302, rs60624335
T > G
SNP
S7A
No VIP available No Clinical Annotations available VA
rs699947 NC_000006.11:g.43736389A>C, NC_000006.12:g.43768652A>C, NG_008732.1:g.3437A>C, NM_001025366.2:c.-2055A>C, NM_001025367.2:c.-2055A>C, NM_001025368.2:c.-2055A>C, NM_001025369.2:c.-2055A>C, NM_001025370.2:c.-2055A>C, NM_001033756.2:c.-2055A>C, NM_001171622.1:c.-2055A>C, NM_001171623.1:c.-2595A>C, NM_001171624.1:c.-2595A>C, NM_001171625.1:c.-2595A>C, NM_001171626.1:c.-2595A>C, NM_001171627.1:c.-2595A>C, NM_001171628.1:c.-2595A>C, NM_001171629.1:c.-2595A>C, NM_001171630.1:c.-2595A>C, NM_001204384.1:c.-2595A>C, NM_001204385.1:c.-2055A>C, NM_001317010.1:c.-2595A>C, NM_003376.5:c.-2055A>C, rs1310065, rs36208051, rs61399354
A > C
SNP
No VIP available CA VA
rs729147 NC_000004.11:g.100333267G>A, NC_000004.12:g.99412110G>A, NM_000673.4:c.*1038C>T, NM_001166504.1:c.*1038C>T, rs3805327, rs56638370, rs59352744
G > A
SNP
No VIP available CA VA
rs7319981 NC_000013.10:g.103723722G>A, NC_000013.11:g.103071372G>A, NG_016648.1:g.475C>T, rs56422021
G > A
SNP
No VIP available CA VA
rs7853758 NC_000009.11:g.86900926G>A, NC_000009.12:g.84286011G>A, NM_001199633.1:c.1381C>T, NM_022127.2:c.1381C>T, NP_001186562.1:p.Leu461=, NP_071410.1:p.Leu461=, NR_037638.2:n.1703C>T, XM_011518905.1:c.1465C>T, XM_011518906.1:c.1465C>T, XM_011518907.1:c.1132C>T, XM_011518908.1:c.742C>T, XP_011517207.1:p.Leu489=, XP_011517208.1:p.Leu489=, XP_011517209.1:p.Leu378=, XP_011517210.1:p.Leu248=, XR_929832.1:n.1572C>T, XR_930033.1:n.88-3031G>A, rs59483082, rs59559753
G > A
SNP
L461L
No VIP available No Clinical Annotations available VA
rs7995976 NC_000013.10:g.28941060A>C, NC_000013.11:g.28366923A>C, NG_012003.1:g.133206T>G, NM_002019.4:c.2117-9238T>G, rs61179897, rs9513092
A > C
SNP
No VIP available No Clinical Annotations available VA
rs833058 NC_000006.11:g.43731854C>T, NC_000006.12:g.43764117C>T, rs58522910
C > T
SNP
No VIP available CA VA
rs885004 NC_000009.11:g.86909550G>A, NC_000009.12:g.84294635G>A, NM_001199633.1:c.862-360C>T, NM_022127.2:c.862-360C>T, NR_037638.2:n.1184-360C>T, XM_011518905.1:c.946-360C>T, XM_011518906.1:c.946-360C>T, XM_011518907.1:c.613-360C>T, XM_011518908.1:c.223-360C>T, XM_011518909.1:c.946-360C>T, XM_011518910.1:c.946-360C>T, XR_929832.1:n.1073-360C>T, rs59238422
G > A
SNP
No VIP available CA VA
rs9024 NC_000021.8:g.37445313G>A, NC_000021.9:g.36073015G>A, NM_001286789.1:c.*1076G>A, NM_001757.3:c.*133G>A, NR_040084.1:n.377+1866C>T, XM_005261073.1:c.*1076G>A, rs17228577, rs3171443, rs61389789
G > A
SNP
No VIP available CA VA
rs9514091 NC_000013.10:g.103714254G>A, NC_000013.11:g.103061904G>A, NG_016648.1:g.9943C>T, NM_000452.2:c.378-3522C>T, rs57163569
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA130620651

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to anthracyclines and related substances: 41

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. International journal of cancer. Journal international du cancer. 2015. Hein Alexander, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nature reviews. Clinical oncology. 2015. Brown Sherry-Ann, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature genetics. 2015. Aminkeng Folefac, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood. 2015. Moriyama Takaya, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies. The pharmacogenomics journal. 2015. Megías-Vericat J E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget. 2015. Fagerholm Rainer, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. European journal of clinical pharmacology. 2015. He Hui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics. 2014. Khrunin Andrey V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014. Wang Xuexia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-Fluorouracil combination chemotherapy. PloS one. 2014. Geng Ruixuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatric blood & cancer. 2013. Visscher H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013. Hlaváč Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Relling Mary V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and genomics. 2011. Jamieson David, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes--A report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Blanco Javier G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Visscher Henk, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncology reports. 2011. Kolesar Jill M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Current medical research and opinion. 2010. Stingl Julia Carolin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. The pharmacogenomics journal. 2010. Gréen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics. 2010. Hammer Christian, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The pharmacogenomics journal. 2010. Cizmarikova M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leukemia & lymphoma. 2009. Rajić Vladan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Choi Ji-Yeob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Advanced drug delivery reviews. 2009. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer research. 2009. DeMichele Angela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug metabolism and disposition: the biological fate of chemicals. 2009. Bains Onkar S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009. Chang H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature genetics. 2008. Fagerholm Rainer, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008. Blanco Javier G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and genomics. 2008. Maggini Valentina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer science. 2008. Lal Suman, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. International journal of cancer. Journal international du cancer. 2006. Kim Dong Hwan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005. Wojnowski Leszek, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. International journal of oncology. 2003. Kafka Ariane, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002. Blanco Javier G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Molecular pharmacology. 2001. Siegel D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999. Legrand O, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999. Siegel D, et al. PubMed

Clinical Trials

These are trials that mention anthracyclines and related substances and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.